Drug discovery company Scynexis has appointed Dr. Vivian Doelling as vice president of animal health.
Doelling brings to the Durham company more than 20 years of experience in animal health. She has done research and development for therapeutic proteins and vaccines for human and animal use.
Before coming to Scynexis, Doelling worked as a consultant for the biotechnology and animal health industries where her work concentrated in product development, technology assessment, IP portfolio management, licensing, commercialization and strategic planning. And before that she was vice president of research and development for Embrex and director of research and development after Pfizer Animal Health acquired Embrex.
“Vivian’s extensive background in animal health will play a key role in the development and growth of our animal health business, expanding our research beyond parasitology,” Scynexis President and CEO Yves Ribeill said in a statement. “Her contributions to Scynexis will be important as we continue to expand our offerings to our animal health partners and to identify new drug candidates, such as SCY-641 for the treatment of canine keratoconjunctivitis sicca.”
